Market closed · data as of 28 Aug 2026 · source NSE via Alphave. Open the live chart →
J.B. Chemicals & Pharmaceuticals (JB Pharma), controlled by KKR since 2020, is a branded formulations company whose domestic portfolio is anchored by legacy mega-brands Rantac (ranitidine), Metrogyl and Cilacar (cilnidipine), expanded via acquisitions in cardiology and other chronic therapies (e.g., Azmarda, Razel). It also has international generics, a large CDMO business in medicated lozenges, and exports to Russia/CIS, South Africa and the US. Revenue is led by India branded formulations, with the lozenges CMO a differentiated global niche.
It ranks among the top-25 Indian pharma companies domestically and is one of the world's largest CDMO manufacturers of medicated lozenges.
J.B. Chemicals & Pharmaceuticals Ltd. is a constituent of NIFTY 500, NIFTY PHARMA, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from J.B. Chemicals & Pharmaceuticals Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 45.16 | 42.45 | 35.66 |
| Book value / share (₹) | 258.98 | 220.51 | 188.36 |
| Return on equity | 17.1% | 0.3% | -0.5% |
| Return on capital employed | 21.1% | 23.6% | 24.3% |
| Operating margin | 22.3% | 22.0% | 21.8% |
| Net margin | 17.1% | 16.8% | 15.9% |
| EBITDA | ₹1,107 Cr | ₹1,032 Cr | ₹897 Cr |
| Free cash flow | ₹704 Cr | ₹782 Cr | ₹539 Cr |
| Total debt | ₹0 Cr | ₹14 Cr | ₹357 Cr |
| Debt to equity | 0.00 | 0.00 | 0.12 |
| Interest coverage | 166.1 | 73.4 | 17.1 |
| Current ratio | 4.98 | 3.06 | 2.15 |
| Shares outstanding | 16,06,00,000 | 15,57,00,000 | 15,52,00,000 |
Open the full income statement, balance sheet and cash flow for JBCHEPHARM →
As disclosed for the quarter ended 31 Mar 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.